Latest News and Press Releases

SYDNEY, AUSTRALIA--(Marketwire - September 20, 2010) -  Pharmaceutical development company, Novogen Limited (ASX: NRT) (NASDAQ: NVGN) has appointed three new Directors. Of the three...

SYDNEY, AUSTRALIA--(Marketwire - June 18, 2010) - Novogen Limited's subsidiary, Marshall Edwards, Inc. (NASDAQ: MSHL), has announced today the appointment of Mr. Thomas Zech as its CFO and Company...

SAN DIEGO, CA--(Marketwire - June 17, 2010) -  Marshall Edwards, Inc. (NASDAQ: MSHL), an oncology company focused on the clinical development of novel anti-cancer therapeutics, announced today...

SYDNEY, AUSTRALIA and SAN DIEGO, CA--(Marketwire - June 3, 2010) -  Marshall Edwards, Inc. (NASDAQ: MSHL), an oncology company focused on the clinical development of novel anti-cancer...

SYDNEY, AUSTRALIA and SAN DIEGO, CA--(Marketwire - June 1, 2010) - Marshall Edwards, Inc. (NASDAQ: MSHL), an oncology company focused on the clinical development of novel anti-cancer therapeutics,...

SAN DIEGO, CA--(Marketwire - May 21, 2010) -  Marshall Edwards, Inc., (NASDAQ: MSHL). An abstract titled "A phase II study of oral phenoxodiol in castrate and non-castrate prostate cancer...

SYDNEY, AUSTRALIA and SAN DIEGO, CA--(Marketwire - April 26, 2010) - Marshall Edwards, Inc. (NASDAQ: MSHLD), an oncology company focused on the clinical development of novel anti-cancer therapeutics,...

NEW CANAAN, CT--(Marketwire - March 31, 2010) - Marshall Edwards, Inc. (NASDAQ: MSHL) (NASDAQ: MSHLD), a specialist oncology company focusing on the clinical development of novel anti-cancer...

SYDNEY, AUSTRALIA and NEW CANAAN, CT--(Marketwire - December 1, 2009) - Novogen Limited advises that CEO and Managing Director Christopher Naughton will cease his employment with the Company from...

NEW CANAAN, CT and SYDNEY, AUSTRALIA--(Marketwire - August 5, 2009) - Novogen Limited (ASX: NRT) (NASDAQ: NVGN) and Marshall Edwards, Inc. (NASDAQ: MSHL) have concluded a license agreement for...